Immune-related adverse events linked to improved pembrolizumab outcomes in urothelial carcinoma - Urology Times

Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.

Findings presented at the 2022 AUA Annual Meeting suggest that immune-related adverse events (irAEs) may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab … [+3888 chars]

full article...